daunorubicin has been researched along with sdz psc 833 in 47 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 23 (48.94) | 18.2507 |
| 2000's | 19 (40.43) | 29.6817 |
| 2010's | 5 (10.64) | 24.3611 |
| 2020's | 0 (0.00) | 2.80 |
| Authors | Studies |
|---|---|
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Friche, E; Jensen, PB; Nissen, NI | 1 |
| Boesch, D; Loor, F; Muller, K; Pourtier-Manzanedo, A | 1 |
| Jiang, XR; Kelsey, SM; Newland, AC; Wu, YL | 1 |
| Jachez, B; Loor, F | 1 |
| Boesch, D; Loor, F | 1 |
| Böhme, M; Büchler, M; Jedlitschky, G; Keppler, D; Leier, I | 1 |
| Barrand, MA; Center, MS; Rhodes, T; Twentyman, PR | 1 |
| Didier, A; Loor, F; Wenger, J | 1 |
| Davey, MW; Davey, RA; Hargrave, RM | 1 |
| Asschert, J; de Vries, E; Müller, M; van der Kolk, D; Vellenga, E | 1 |
| Cayre, A; Finat-Duclos, F; Maublant, J; Moins, N; Verrelle, P | 2 |
| Borg, AG; Burgess, R; Fisher, A; Grey, M; Wood, P; Yin, JA | 1 |
| Coley, HM; Sargent, JM; Taylor, C; Williamson, C | 1 |
| Clausen, OP; De Angelis, P; Lehne, G; Rugstad, HE | 1 |
| den Boer, ML; Henze, G; Janka-Schaub, GE; Kazemier, KM; Pieters, R; Veerman, AJ | 1 |
| Bour, C; Colosetti, P; Guerci, AP; Guerci, O; Kataki, A; Marchal, S; Merlin, JL | 1 |
| Fukushima, T; Imamura, S; Misaki, H; Ueda, T; Urasaki, Y; Yamashita, T; Yamauchi, T; Yoshio, N | 1 |
| Bettaieb, A; Côme, MG; Larsen, AK; Laurent, G; Skladanowski, A | 1 |
| De Angelis, P; den Boer, M; Lehne, G; Rugstad, HE | 1 |
| Langabeer, S; Pallis, M; Russell, NH; Turzanski, J | 1 |
| Baer, M; Caligiuri, M; Dodge, RK; George, SL; Lee, EJ; Lemke, S; Powell, BL; Schiffer, CA; Smith, R; Szatrowski, TP | 1 |
| de Waal, E; Lankelma, J; Westerhoff, HV; Wielinga, PR | 1 |
| den Boer, M; Lehne, G; Mørkrid, L; Rugstad, HE | 1 |
| Covelli, A; Elmhorn-Rosenborg, A; Gruber, A; Gustavsson, B; Juliusson, G; Lehman, S; Liliemark, E; Liliemark, J; Möllgård, L; Paul, C; Stenke, L; Sundman-Engberg, B; Tidefelt, U; Xu, D | 1 |
| Borst, P; Sarkadi, B; Smith, AJ; Szabo, K; Szakacs, G; van Helvoort, A; van Meer, G; Varadi, A; Welker, E | 1 |
| Atadja, P; Cohen, D; Roninson, IB; Uchiyama, N; Watanabe, T | 1 |
| Bour-Dill, C; Giroux, B; Marchal, S; Merlin, JL; Poullain, MG; Ramacci, C | 1 |
| Bootle, D; Charlton, P; Dangerfield, W; Liddle, C; Mistry, P; Okiji, S; Plumb, JA; Stewart, AJ; Templeton, D | 1 |
| Dalton, W; Dorr, R; Greer, J; Grogan, T; Karanes, C; List, AF; Litchman, M; Moore, J; Pearce, T; Roe, D; Schiller, G; Spier, C; Weinberger, B | 1 |
| Hellmann, K; Sargent, JM; Taylor, CG; Williamson, CJ; Yardley, C | 1 |
| Aszalos, A; Bocsi, J; Ladányi, A; Szende, B | 1 |
| Kang, W; Weiss, M | 1 |
| Ben-Am, M; Burnett, A; Capdeville, R; Dekker, A; Ferrant, C; Gratwohl, A; Kovacsovics, T; Löwenberg, B; Ossenkoppele, G; Pfister, C; Rosenkranz, G; Sonneveld, P; Vellenga, E; Verhoef, G; Vossebeld, P; Yin, L | 1 |
| Anastasi, J; Baer, MR; Bloomfield, CD; Caligiuri, MA; Dodge, RK; George, SL; Kolitz, JE; Larson, RA; Minderman, H; O'Loughlin, KL; Powell, BL; Schiffer, CA | 1 |
| Baer, M; Becknell, B; Bloomfield, CD; Caligiuri, MA; Crawford, J; Dodge, RK; Farag, SS; Fehniger, TA; George, SL; Larson, RA; Lee, EJ; Schiffer, CA; Silverman, LR | 1 |
| Björkholm, M; Brinch, L; Evensen, S; Gruber, A; Gustavsson, B; Hedenus, M; Juliusson, G; Liliemark, J; Löfvenberg, E; Nesthus, I; Paul, C; Simonsson, B; Sjo, M; Stenke, L; Tangen, JM; Tidefelt, U; Udén, AM | 1 |
| Allen, SL; Bloomfield, CD; Caligiuri, MA; Dodge, RK; George, SL; Hoke, E; Hurd, DD; Kolitz, JE; Larson, RA; Moore, JO; Powell, BL; Shea, TC; Vardiman, JW; Velez-Garcia, E | 1 |
| Burnett, AK; Crump, M; Dugan, M; Ferrant, A; Fey, MF; Knauf, WU; Löwenberg, B; Ossenkoppele, GJ; Piccaluga, PP; Selleslag, D; Shepherd, J; Sonneveld, P; Theobald, M; van der Holt, B; Vellenga, E; Verhoef, GE | 1 |
| Ades, S; Gould, CJ; Jones, GK; Levy, SB; Maxfield, LF | 1 |
| Bacsó, Z; Fenyvesi, F; Goda, K; Juhász, I; Krasznai, Z; Márián, T; Megyeri, A; Nagy, H; Szabó, G; Vecsernyés, M | 1 |
| Burnett, AK; Dennis, M; Goldstone, A; Hills, RK; McMullin, MF; Milligan, D; Pallis, M; Prentice, A; Russell, N; Sellwood, E; Wheatley, K | 1 |
| Allen, SL; Baer, MR; Bloomfield, CD; DeAngelo, DJ; George, SL; Hars, V; Hoke, E; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Powell, BL; Shea, TC; Stock, W; Vardiman, JW; Vij, R | 1 |
| Aouali, N; Dumontet, C; Eddabra, L; El Btaouri, H; Madoulet, C; Malagarie-Cazenave, S; Morjani, H | 1 |
| Allen, SL; Bakan, CE; Benson, DM; Bloomfield, CD; Caligiuri, MA; Deangelo, DJ; George, SL; Hars, V; Hoke, E; Kolitz, JE; Larson, RA; Maharry, K; Marcucci, G; Powell, BL; Shea, TC; Stock, W; Vij, R | 1 |
| Bhuiyan, H; Broom, OJ; Islam, S; Lehtiö, J; Lindahl, A; Linnarsson, S; Nordström, A; Stäubert, C; Zhu, Y | 1 |
12 trial(s) available for daunorubicin and sdz psc 833
| Article | Year |
|---|---|
Parallel phase I studies of daunorubicin given with cytarabine and etoposide with or without the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age or older with acute myeloid leukemia: results of cancer and leukemia g
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Male; Middle Aged | 1999 |
P-Glycoprotein inhibitor valspodar (PSC 833) increases the intracellular concentrations of daunorubicin in vivo in patients with P-glycoprotein-positive acute myeloid leukemia.
Topics: Aged; Aged, 80 and over; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Daunorubicin; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged | 2000 |
Phase I/II study of the P-glycoprotein modulator PSC 833 in patients with acute myeloid leukemia.
Topics: Acute Disease; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; Cyclosporins; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Interactions; Female; Humans; Infusions, Intravenous; Leukemia, Myeloid; Male; Middle Aged; Risk Factors; Treatment Outcome | 2001 |
Dose-finding study of valspodar (PSC 833) with daunorubicin and cytarabine to reverse multidrug resistance in elderly patients with previously untreated acute myeloid leukemia.
Topics: Acute Disease; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cohort Studies; Cyclosporins; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Edema; Female; Fever; Humans; Hypokalemia; Leukemia, Myeloid; Male; Maximum Tolerated Dose; Middle Aged; Nausea; Neoplasm Proteins; Remission Induction; Survival Analysis; Survival Rate; Treatment Outcome | 2000 |
Phase 3 study of the multidrug resistance modulator PSC-833 in previously untreated patients 60 years of age and older with acute myeloid leukemia: Cancer and Leukemia Group B Study 9720.
Topics: Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Resistance, Multiple; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Logistic Models; Male; Middle Aged; Remission Induction | 2002 |
Postremission therapy with low-dose interleukin 2 with or without intermediate pulse dose interleukin 2 therapy is well tolerated in elderly patients with acute myeloid leukemia: Cancer and Leukemia Group B study 9420.
Topics: Acute Disease; Age Factors; Aged; Antineoplastic Combined Chemotherapy Protocols; Combined Modality Therapy; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Drug Administration Schedule; Etoposide; Fatigue; Gene Expression Regulation, Neoplastic; Hematologic Diseases; Humans; Immunologic Factors; Interleukin-2; Killer Cells, Natural; Leukemia, Myeloid; Life Tables; Middle Aged; Nausea; Neoplasm Proteins; NK Cell Lectin-Like Receptor Subfamily K; Receptors, Immunologic; Receptors, Natural Killer Cell; Recombinant Fusion Proteins; Remission Induction; Survival Analysis; Treatment Outcome | 2002 |
A phase I/II study of the MDR modulator Valspodar (PSC 833) combined with daunorubicin and cytarabine in patients with relapsed and primary refractory acute myeloid leukemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antineoplastic Combined Chemotherapy Protocols; Area Under Curve; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cause of Death; Cyclosporins; Cytarabine; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Humans; Leukemia, Myeloid; Middle Aged; Remission Induction; Salvage Therapy; Treatment Outcome | 2003 |
Dose escalation studies of cytarabine, daunorubicin, and etoposide with and without multidrug resistance modulation with PSC-833 in untreated adults with acute myeloid leukemia younger than 60 years: final induction results of Cancer and Leukemia Group B
Topics: Acute Disease; Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Female; Humans; Leukemia, Myeloid; Logistic Models; Male; Middle Aged; Survival Analysis; Treatment Outcome | 2004 |
The value of the MDR1 reversal agent PSC-833 in addition to daunorubicin and cytarabine in the treatment of elderly patients with previously untreated acute myeloid leukemia (AML), in relation to MDR1 status at diagnosis.
Topics: Aged; Aged, 80 and over; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Daunorubicin; Drug Therapy, Combination; Female; Follow-Up Studies; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Survival Rate; Treatment Outcome | 2005 |
The impact of dose escalation and resistance modulation in older patients with acute myeloid leukaemia and high risk myelodysplastic syndrome: the results of the LRF AML14 trial.
Topics: Adult; Age Factors; Aged; Aged, 80 and over; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Cytogenetic Analysis; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance, Neoplasm; Female; Humans; Leukemia, Myeloid, Acute; Leukocyte Count; Male; Middle Aged; Multivariate Analysis; Myelodysplastic Syndromes; Prognosis; Remission Induction; Survival Rate | 2009 |
P-glycoprotein inhibition using valspodar (PSC-833) does not improve outcomes for patients younger than age 60 years with newly diagnosed acute myeloid leukemia: Cancer and Leukemia Group B study 19808.
Topics: Adolescent; Adult; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Cytarabine; Daunorubicin; Etoposide; Female; Humans; Leukemia, Myeloid, Acute; Male; Middle Aged; Remission Induction; Survival Rate; Treatment Outcome; Young Adult | 2010 |
Recombinant interleukin-2 in patients aged younger than 60 years with acute myeloid leukemia in first complete remission: results from Cancer and Leukemia Group B 19808.
Topics: Age Factors; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Cytarabine; Daunorubicin; Disease-Free Survival; Etoposide; Female; Humans; Interleukin-2; Leukemia, Myeloid, Acute; Male; Middle Aged; Recombinant Proteins; Remission Induction; Survival Rate; Treatment Outcome | 2014 |
35 other study(ies) available for daunorubicin and sdz psc 833
| Article | Year |
|---|---|
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Comparison of cyclosporin A and SDZ PSC833 as multidrug-resistance modulators in a daunorubicin-resistant Ehrlich ascites tumor.
Topics: Animals; Carcinoma, Ehrlich Tumor; Cyclosporine; Cyclosporins; Daunorubicin; Drug Interactions; Drug Resistance; Tumor Cells, Cultured; Vincristine | 1992 |
Restoration of daunomycin retention in multidrug-resistant P388 cells by submicromolar concentrations of SDZ PSC 833, a nonimmunosuppressive cyclosporin derivative.
Topics: Amiodarone; Animals; Cyclosporins; Daunorubicin; Dose-Response Relationship, Drug; Drug Resistance; Flow Cytometry; Leukemia, Experimental; Leukemia, Myeloid; Microscopy, Fluorescence; Quinacrine; Quinidine; Tumor Cells, Cultured; Verapamil | 1991 |
Circumvention of P-glycoprotein-mediated drug resistance in human leukaemic cells by non-immunosuppressive cyclosporin D analogue, SDZ PSC 833.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Cyclosporine; Cyclosporins; Daunorubicin; Drug Resistance, Multiple; Fluorescent Antibody Technique; Humans; Leukemia, Erythroblastic, Acute; Leukemia, T-Cell; Tumor Cells, Cultured | 1995 |
Atypical multi-drug resistance (MDR): low sensitivity of a P-glycoprotein-expressing human T lymphoblastoid MDR cell line to classical P-glycoprotein-directed resistance-modulating agents.
Topics: Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cell Division; Cyclosporine; Cyclosporins; Daunorubicin; Drug Resistance; Flow Cytometry; Humans; Leukemia-Lymphoma, Adult T-Cell; Membrane Glycoproteins; Peptides, Cyclic; Tumor Cells, Cultured; Verapamil | 1993 |
Extent and persistence of P-glycoprotein inhibition in multidrug-resistant P388 cells after exposure to resistance-modifying agents.
Topics: Amino Acid Sequence; Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carrier Proteins; Cyclosporine; Cyclosporins; Daunorubicin; Drug Resistance; Extracellular Space; Leukemia P388; Membrane Glycoproteins; Mice; Molecular Sequence Data; Peptides, Cyclic; Verapamil | 1994 |
ATP-dependent export pumps and their inhibition by cyclosporins.
Topics: Adenosine Triphosphate; Animals; Bile; Bile Canaliculi; Biological Transport, Active; Carrier Proteins; Cell Membrane; Cyclosporine; Cyclosporins; Daunorubicin; Drug Resistance, Multiple; Immunosuppression Therapy; Leukotriene C4; Male; Rats; Rats, Wistar; Taurocholic Acid | 1994 |
Chemosensitisation and drug accumulation effects of cyclosporin A, PSC-833 and verapamil in human MDR large cell lung cancer cells expressing a 190k membrane protein distinct from P-glycoprotein.
Topics: Carcinoma, Non-Small-Cell Lung; Cyclosporine; Cyclosporins; Daunorubicin; Humans; Lung Neoplasms; Membrane Proteins; Molecular Weight; Neoplasm Proteins; Tumor Cells, Cultured; Verapamil; Vincristine | 1993 |
Decreased uptake of cyclosporin A by P-glycoprotein (Pgp) expressing CEM leukemic cells and restoration of normal retention by Pgp blockers.
Topics: Animals; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cyclosporins; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Flow Cytometry; Humans; Immunosuppressive Agents; Leukemia, Monocytic, Acute; Leukemia, T-Cell; Mice; Peptides, Cyclic; Rhodamines; Tumor Cells, Cultured; Verapamil; Vinblastine | 1995 |
Comparison of drug accumulation in P-glycoprotein-expressing and MRP-expressing human leukaemia cells.
Topics: Antibiotics, Antineoplastic; Antimetabolites, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Buthionine Sulfoximine; Calcium Channel Blockers; Cyclosporins; Daunorubicin; Humans; Idarubicin; Leukemia, T-Cell; Multidrug Resistance-Associated Proteins; Rhodamine 123; Rhodamines; Tumor Cells, Cultured; Verapamil | 1996 |
The combined effects of IL-3 and PSC 833 on daunorubicin- and mitoxantrone cytotoxicity in two growth factor-dependent leukemic cell lines.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Survival; Cyclosporins; Daunorubicin; Dose-Response Relationship, Drug; Drug Interactions; Drug Resistance, Multiple; Drug Synergism; Humans; Interleukin-3; Kinetics; Leukemia; Mitoxantrone; Tumor Cells, Cultured | 1997 |
Comparison between technetium-99m-sestamibi and hydrogen-3-daunomycin myocardial cellular retention in vitro.
Topics: Animals; Animals, Newborn; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cells, Cultured; Cyclosporins; Daunorubicin; Drug Resistance, Neoplasm; Genes, MDR; Heart; In Vitro Techniques; Myocardium; Piperidines; Radionuclide Imaging; Rats; Rats, Wistar; Technetium Tc 99m Sestamibi; Triazines; Tritium; Verapamil | 1997 |
Effect on cell kill of addition of multidrug resistance modifiers cyclosporin A and PSC 833 to cytotoxic agents in acute myeloid leukaemia.
Topics: Acute Disease; Adolescent; Adult; Aged; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport; Cell Survival; Coloring Agents; Cyclosporine; Cyclosporins; Cytarabine; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Etoposide; Female; Humans; Idarubicin; Leukemia, Myeloid; Male; Middle Aged; Mitoxantrone; Tetrazolium Salts; Thiazoles; Tumor Cells, Cultured | 1997 |
Evidence of ABC transporters in fresh tumor cells from patients with ovarian cancer.
Topics: Adenocarcinoma; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cyclosporins; Daunorubicin; Drug Resistance, Multiple; Female; Flow Cytometry; Humans; Immunohistochemistry; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Ovarian Neoplasms; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles | 1998 |
Differential resistance to anthracyclines in P-glycoprotein-expressing human hepatoma cells.
Topics: Aclarubicin; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carcinoma, Hepatocellular; Cyclosporins; Daunorubicin; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Epirubicin; Humans; Liver Neoplasms; Tumor Cells, Cultured | 1998 |
The modulating effect of PSC 833, cyclosporin A, verapamil and genistein on in vitro cytotoxicity and intracellular content of daunorubicin in childhood acute lymphoblastic leukemia.
Topics: Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Cell Survival; Cyclosporine; Cyclosporins; Daunorubicin; Drug Resistance, Neoplasm; Genistein; Humans; In Vitro Techniques; Multidrug Resistance-Associated Proteins; Precursor Cell Lymphoblastic Leukemia-Lymphoma; Verapamil | 1998 |
Influence of SDZ-PSC833 on daunorubicin intracellular accumulation in bone marrow specimens from patients with acute myeloid leukaemia.
Topics: Acute Disease; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Bone Marrow; Cyclosporine; Cyclosporins; Daunorubicin; Drug Interactions; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Immunosuppressive Agents; Leukemia, Myeloid; Tumor Cells, Cultured | 1998 |
Effect of PSC 833 on the cytotoxicity of idarubicin and idarubicinol in multidrug-resistant K562 cells.
Topics: Antibiotics, Antineoplastic; Antineoplastic Combined Chemotherapy Protocols; Cyclosporins; Daunorubicin; Drug Resistance, Multiple; Humans; Idarubicin; K562 Cells | 1999 |
Comparative 99mTc-sestamibi and 3H-daunomycin uptake in human carcinoma cells: relation to the MDR phenotype and effects of reversing agents.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Cyclosporins; Daunorubicin; Drug Resistance, Multiple; Humans; Piperidines; Radiopharmaceuticals; Reverse Transcriptase Polymerase Chain Reaction; Technetium Tc 99m Sestamibi; Triazines; Tritium; Tumor Cells, Cultured; Verapamil | 1999 |
Alteration of the daunorubicin-triggered sphingomyelin-ceramide pathway and apoptosis in MDR cells: influence of drug transport abnormalities.
Topics: Apoptosis; Cell Cycle; Ceramides; Cyclosporins; Daunorubicin; DNA Fragmentation; Drug Resistance, Multiple; HL-60 Cells; Humans; Kinetics; Signal Transduction; Sphingomyelin Phosphodiesterase; Sphingomyelins; Time Factors; Vincristine | 1999 |
Growth inhibition, cytokinesis failure and apoptosis of multidrug-resistant leukemia cells after treatment with P-glycoprotein inhibitory agents.
Topics: Antineoplastic Agents; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Daunorubicin; Dibenzocycloheptenes; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Leukemia; Peptides, Cyclic; Phenotype; Quinolines; Tumor Cells, Cultured | 1999 |
Reproducible flow cytometric methodology for measuring multidrug resistance in leukaemic blasts.
Topics: ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; Blast Crisis; Bone Marrow Cells; Cyclosporine; Cyclosporins; Daunorubicin; Drug Resistance, Multiple; Flow Cytometry; Genes, MDR; Humans; Leukemia, Myeloid, Acute; Multidrug Resistance-Associated Proteins; Reproducibility of Results | 1999 |
In vitro transepithelial drug transport by on-line measurement: cellular control of paracellular and transcellular transport.
Topics: Algorithms; Animals; Biological Transport, Active; Cattle; Cell Line; Cells, Cultured; Chemical Phenomena; Chemistry, Physical; Cyclosporins; Daunorubicin; Dextrans; Dogs; Epithelial Cells; Fluorescein-5-isothiocyanate; Genes, MDR; Humans; Idarubicin; Models, Biological; Online Systems; Tight Junctions | 1999 |
Diverse effects of P-glycoprotein inhibitory agents on human leukemia cells expressing the multidrug resistance protein (MRP).
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; Cyclosporins; Daunorubicin; Dibenzocycloheptenes; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Fluorescence; Humans; Leukemia, Myeloid; Peptides, Cyclic; Quinolines; Tumor Cells, Cultured | 2000 |
MDR3 P-glycoprotein, a phosphatidylcholine translocase, transports several cytotoxic drugs and directly interacts with drugs as judged by interference with nucleotide trapping.
Topics: Adenosine Triphosphate; Animals; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Biological Transport; Cell Polarity; Cells, Cultured; Cyclosporine; Cyclosporins; Cytotoxins; Daunorubicin; Digoxin; Epithelial Cells; Humans; Ivermectin; Kidney; Paclitaxel; Pharmaceutical Preparations; Phosphatidylcholines; Recombinant Proteins; Spodoptera; Swine; Verapamil; Vinblastine | 2000 |
Altered activity of MDR-reversing agents on KB3-1 cells transfected with Gly(185)-->Val human P-glycoprotein.
Topics: Adenosine Triphosphatases; Amino Acid Substitution; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Biological Transport, Active; Calcium Channel Blockers; Carcinoma, Squamous Cell; Colchicine; Cyclosporine; Cyclosporins; Daunorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Humans; Neoplasm Proteins; Paclitaxel; Point Mutation; Structure-Activity Relationship; Transfection; Tumor Cells, Cultured; Verapamil; Vinblastine | 2000 |
Modulation of daunorubicin cellular resistance by combination of P-glycoprotein blockers acting on drug efflux and intracellular drug sequestration in Golgi vesicles.
Topics: Adenocarcinoma; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; ATP-Binding Cassette Transporters; beta 2-Microglobulin; Biological Transport; Breast Neoplasms; Cyclosporins; Daunorubicin; DNA Primers; Dose-Response Relationship, Drug; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Gene Expression Regulation, Neoplastic; Golgi Apparatus; Humans; Microscopy, Fluorescence; Multidrug Resistance-Associated Proteins; Neoplasm Proteins; Phenotype; Piperidines; Triazines; Tumor Cells, Cultured; Vault Ribonucleoprotein Particles | 2000 |
In vitro and in vivo reversal of P-glycoprotein-mediated multidrug resistance by a novel potent modulator, XR9576.
Topics: Acridines; Animals; Antibiotics, Antineoplastic; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Azides; Binding, Competitive; Cell Division; Cyclosporins; Daunorubicin; Dihydropyridines; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Drug Synergism; Female; Humans; Isoquinolines; Mice; Mice, Inbred BALB C; Mice, Nude; Neoplasm Transplantation; Neoplasms, Experimental; Paclitaxel; Quinolines; Tetrahydroisoquinolines; Time Factors; Treatment Outcome; Tritium; Xenograft Model Antitumor Assays | 2001 |
Dexrazoxane significantly impairs the induction of doxorubicin resistance in the human leukaemia line, K562.
Topics: Antibiotics, Antineoplastic; Antineoplastic Agents; Antineoplastic Combined Chemotherapy Protocols; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Daunorubicin; Doxorubicin; Drug Interactions; Drug Resistance, Neoplasm; Gene Expression Regulation; Humans; K562 Cells; Phenotype; Razoxane; RNA, Messenger | 2001 |
Induction of apoptosis in MDR1 expressing cells by daunorubicin with combinations of suboptimal concentrations of P-glycoprotein modulators.
Topics: 3T3 Cells; Animals; Antibiotics, Antineoplastic; Apoptosis; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cell Division; Cyclosporins; Daunorubicin; Drug Combinations; Drug Interactions; G2 Phase; Glycerol; Mice; Verapamil | 2001 |
Influence of P-glycoprotein modulators on cardiac uptake, metabolism, and effects of idarubicin.
Topics: Algorithms; Animals; Antibiotics, Antineoplastic; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporins; Daunorubicin; Heart; Idarubicin; In Vitro Techniques; Male; Myocardium; Rats; Rats, Sprague-Dawley; Stroke Volume; Verapamil | 2001 |
Selection of non-P-glycoprotein mediated high-level etoposide resistant cell lines by adriamycin with P-gp inhibitors.
Topics: Animals; Antigens, Neoplasm; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B; ATP-Binding Cassette Transporters; Blotting, Western; Cell Line, Tumor; Cell Survival; Cyclosporins; Daunorubicin; DNA Topoisomerases, Type II; DNA-Binding Proteins; Dose-Response Relationship, Drug; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Etoposide; Gene Expression Regulation, Neoplastic; Mice; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Verapamil | 2006 |
Complete inhibition of P-glycoprotein by simultaneous treatment with a distinct class of modulators and the UIC2 monoclonal antibody.
Topics: Animals; Antibodies, Monoclonal; ATP Binding Cassette Transporter, Subfamily B, Member 1; Cyclosporine; Cyclosporins; Daunorubicin; Fluoresceins; Humans; Mice; NIH 3T3 Cells; Vinblastine | 2007 |
Accumulation of lactosylceramide and overexpression of a PSC833-resistant P-glycoprotein in multidrug-resistant human sarcoma cells.
Topics: Antibiotics, Antineoplastic; Antigens, CD; ATP Binding Cassette Transporter, Subfamily B, Member 1; Blotting, Western; Cell Proliferation; Cyclosporins; Daunorubicin; Doxorubicin; Drug Resistance, Multiple; Drug Resistance, Neoplasm; Flow Cytometry; Humans; Lactosylceramides; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Sarcoma; Tumor Cells, Cultured | 2011 |
Rewired metabolism in drug-resistant leukemia cells: a metabolic switch hallmarked by reduced dependence on exogenous glutamine.
Topics: 3-Hydroxyacyl CoA Dehydrogenases; Acetyl-CoA C-Acyltransferase; Antineoplastic Agents; ATP Binding Cassette Transporter, Subfamily B, Member 1; Carbon-Carbon Double Bond Isomerases; Cell Line, Tumor; Cyclosporins; Daunorubicin; Drug Resistance, Neoplasm; Drug Synergism; Enoyl-CoA Hydratase; Fatty Acids; Glutamine; Glycolysis; Humans; Leukemia; Metabolome; Oxidation-Reduction; Pantothenic Acid; Perhexiline; Racemases and Epimerases; RNA, Messenger; Transcriptome | 2015 |